妊娠期孕妇亚临床甲减对妊娠结局的影响分析

摘要

Objective To analyze pregnancy pregnant women subclinical JiaJian influence on pregnancy outcome, provide guidance for clinical. Methods Random selection 60 patients admitted to the hospital subclinical JiaJian pregnant women during pregnancy (December 2011 to December 2015) as the research object of this experiment, 60 cases of subclinical Jia-Jian pregnant women during pregnancy to implement computer random group (control group and observation group). Control group 30 cases of subclinical JiaJian pregnant women during pregnancy does not implement drug treatment, the experimen-tal group 30 cases of subclinical JiaJian pregnant women during pregnancy to implement drug treatment, compared two groups of subclinical JiaJian during pregnancy pregnant women before and after treatment serum free thyroxine (FT4), serum free thyroid original three iodine glycine (FT3) and testing for thyroid-stimulating hormone (TSH), pregnancy outcome and neonatal adverse outcomes happen. Results In the control group of subclinical JiaJian pregnant women during pregnancy complications (53.33%) is significantly higher than the experimental group (13.33%), and the observation group, the gesta-tion period of sub clinical hypothyroidism after treatment for pregnant women, FT4, FT3, and TSH levels respectively (13.67± 1.61) pmol/L, (6.87±0.81) pmol/L, (3.51±1.09) mU/L, adverse neonatal outcomes occur rate was 10.00%, control group preg-nancy sub clinical hypothyroidism after treatment for pregnant women, FT4, FT3, and TSH levels respectively (11.13±1.45) pmol/L, (5.06±0.51) pmol/L,(8.24±1.57) mU/L, adverse neonatal outcomes occurred rate was 40.00%. the comparison shows that,and the experimental group and control group in subclinical JiaJian pregnant women during pregnancy after treatment, FT4, FT3, TSH and incidence of neonatal adverse outcome exists obvious difference, P< 0.05. Conclusion Pregnancy sub-clinical JiaJian easy to raise the risk of pregnant complications incidence and neonatal adverse outcomes, in order to ensure the safety of maternal and infant clinical response to pregnant women to carry out effective treatment.%目的：分析妊娠期孕妇亚临床甲减对妊娠结局的影响,为临床提供指导。方法随机抽取入住该院的60例妊娠期亚临床甲减孕妇(2011年12月—2015年12月)作为该次实验的研究对象,对60例妊娠期亚临床甲减孕妇实施计算机随机分组(对照组和观察组)。对照组30例妊娠期亚临床甲减孕妇不实施药物治疗,观察组30例妊娠期亚临床甲减孕妇实施药物治疗,分析比较两组妊娠期亚临床甲减孕妇治疗前后血清游离甲状腺素(FT4)、血清游离三碘甲状腺原氨酸(FT3)、促甲状腺激素(TSH)情况、妊娠结局及新生儿不良结局发生情况。结果对照组妊娠期亚临床甲减孕妇的并发症发生率(53.33%)显著高于观察组(13.33%),且观察组妊娠期亚临床甲减孕妇治疗后FT4、FT3、TSH水平分别为(13.67±1.61)pmol/L、(6.87±0.81)pmol/L、(3.51±1.09)mU/L,新生儿不良结局发生率为10.00%,对照组妊娠期亚临床甲减孕妇治疗后FT4、FT3、TSH水平分别为(11.13±1.45)pmol/L、(5.06±0.51)pmol/L、(8.24±1.57)mU/L,新生儿不良结局发生率为40.00%,比较可知,观察组和对照组妊娠期亚临床甲减孕妇治疗后FT4、FT3、TSH情况以及新生儿不良结局发生率对比差异有统计学意义,P﹤0.05。结论妊娠期亚临床甲减易增加孕妇发生并发症的机率以及新生儿不良结局发生率,为保证母婴安全,临床应对孕妇实施有效治疗。